Nimotuzumab-induced hypertension: A maiden case report

Ommurugan Balaji; D. Amita Priya; Navin Patil

doi:10.22159/ajpcr.2017.v10i4.16868

Nimotuzumab-induced hypertension: A maiden case report

Ommurugan Balaji, D. Amita Priya, Navin Patil

Department of Pharmacology, Kasturba Medical College, Manipal

Research output: Contribution to journal › Article › peer-review

Abstract

Nimotuzumab is one among the latest humanized monoclonal antibody targeting against epidermal growth factor receptor (EGFR). It is approved for head and neck squamous cancer in India, Srilanka, Cuba and Argentina, for glioma in Cuba, Argentina and Ukraine and nasopharyngeal cancer in China. Hypertension is most common with bevacizumab and cetuximab, which are monoclonal antibodies against EGFR. Hence, we report here a case of nimotuzumab-induced hypertension in a 70-year-old man treated for vocal cord carcinoma.

Original language	English
Pages (from-to)	8-9
Number of pages	2
Journal	Asian Journal of Pharmaceutical and Clinical Research
Volume	10
Issue number	4
DOIs	https://doi.org/10.22159/ajpcr.2017.v10i4.16868
Publication status	Published - 01-04-2017

All Science Journal Classification (ASJC) codes

Pharmacology
Pharmaceutical Science
Pharmacology (medical)

Access to Document

10.22159/ajpcr.2017.v10i4.16868

Fingerprint Dive into the research topics of 'Nimotuzumab-induced hypertension: A maiden case report'. Together they form a unique fingerprint.

Cite this

@article{69686afc4ef34c298c5cd592a43fb2b4,

title = "Nimotuzumab-induced hypertension: A maiden case report",

abstract = "Nimotuzumab is one among the latest humanized monoclonal antibody targeting against epidermal growth factor receptor (EGFR). It is approved for head and neck squamous cancer in India, Srilanka, Cuba and Argentina, for glioma in Cuba, Argentina and Ukraine and nasopharyngeal cancer in China. Hypertension is most common with bevacizumab and cetuximab, which are monoclonal antibodies against EGFR. Hence, we report here a case of nimotuzumab-induced hypertension in a 70-year-old man treated for vocal cord carcinoma.",

author = "Ommurugan Balaji and {Amita Priya}, D. and Navin Patil",

year = "2017",

month = apr,

day = "1",

doi = "10.22159/ajpcr.2017.v10i4.16868",

language = "English",

volume = "10",

pages = "8--9",

journal = "Asian Journal of Pharmaceutical and Clinical Research",

issn = "0974-2441",

publisher = "Innovare Academics Sciences Pvt. Ltd",

number = "4",

}

TY - JOUR

T1 - Nimotuzumab-induced hypertension

T2 - A maiden case report

AU - Balaji, Ommurugan

AU - Amita Priya, D.

AU - Patil, Navin

PY - 2017/4/1

Y1 - 2017/4/1

N2 - Nimotuzumab is one among the latest humanized monoclonal antibody targeting against epidermal growth factor receptor (EGFR). It is approved for head and neck squamous cancer in India, Srilanka, Cuba and Argentina, for glioma in Cuba, Argentina and Ukraine and nasopharyngeal cancer in China. Hypertension is most common with bevacizumab and cetuximab, which are monoclonal antibodies against EGFR. Hence, we report here a case of nimotuzumab-induced hypertension in a 70-year-old man treated for vocal cord carcinoma.

AB - Nimotuzumab is one among the latest humanized monoclonal antibody targeting against epidermal growth factor receptor (EGFR). It is approved for head and neck squamous cancer in India, Srilanka, Cuba and Argentina, for glioma in Cuba, Argentina and Ukraine and nasopharyngeal cancer in China. Hypertension is most common with bevacizumab and cetuximab, which are monoclonal antibodies against EGFR. Hence, we report here a case of nimotuzumab-induced hypertension in a 70-year-old man treated for vocal cord carcinoma.

UR - http://www.scopus.com/inward/record.url?scp=85017096097&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017096097&partnerID=8YFLogxK

U2 - 10.22159/ajpcr.2017.v10i4.16868

DO - 10.22159/ajpcr.2017.v10i4.16868

M3 - Article

AN - SCOPUS:85017096097

VL - 10

SP - 8

EP - 9

JO - Asian Journal of Pharmaceutical and Clinical Research

JF - Asian Journal of Pharmaceutical and Clinical Research

SN - 0974-2441

IS - 4

ER -